Journal
BRAIN BEHAVIOR AND IMMUNITY
Volume 49, Issue -, Pages 188-196Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbi.2015.05.007
Keywords
Neuroinflammation; Pilocarpine; Proteasome inhibitors; Pharmaco-resistant seizures
Categories
Funding
- Onyx Pharmaceuticals, Inc., an Amgen
- AICE-FIRE Onlus
- EPITARGET (FP7) [602102]
- Deutsche Forschungsgemeinschaft [SFB 740, SFB TR43]
Ask authors/readers for more resources
The proteasome is the core of the ubiquitin-proteasome system and is involved in synaptic protein metabolism. The incorporation of three inducible immuno-subunits into the proteasome results in the generation of the so-called immunoproteasome, which is endowed of pathophysiological functions related to immunity and inflammation. In healthy human brain, the expression of the key catalytic beta 5i subunit of the immunoproteasome is almost absent, while it is induced in the epileptogenic foci surgically resected from patients with pharmaco-resistant seizures, including temporal lobe epilepsy. We show here that the beta 5i immuno-subunit is induced in experimental epilepsy, and its selective pharmacological inhibition significantly prevents, or delays, 4-aminopyridine-induced seizure-like events in acute rat hippocampal/entorhinal cortex slices. These effects are stronger in slices from epileptic vs normal rats, likely due to the more prominent beta 5i subunit expression in neurons and glia cells of diseased tissue. beta 5i subunit is transcriptionally induced in epileptogenic tissue likely by Toll-like receptor 4 signaling activation, and independently on promoter methylation. The recent availability of selective beta 5i subunit inhibitors opens up novel therapeutic opportunities for seizure inhibition in drug-resistant epilepsies. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available